Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX005N in adults with moderate-to-severe atopic dermatitis – long-term safety
CTR20231446Phase 2Completed
- Sponsor
- Qyuns Therapeutics
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QX005N in atopic dermatitis (AD), sponsored by Qyuns Therapeutics. Started May 2023; status: completed.
02
Drugs
QX005N
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20231446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231446.